Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pralatrexate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR known ✓ | P00374 | 14/20 | 1.00 |
| ▸ | FOLR1 | P15328 | 2/20 | 1.00 |
| ▸ | SLC19A1 | P41440 | 2/20 | 1.00 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | TLR4 | O00206 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | TYMS | P04818 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | GART | P22102 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pralatrexate SCHEMBL29904921 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL1889869 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL15075302 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL1890561 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL2336143 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL29355142 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL29904925 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL17554355 | 0.99 | DHFR (0.98) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL17554353 | 0.99 | DHFR (0.98) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL28201941 | 0.99 | DHFR (0.98) | DHFRFOLR1SLC19A1SLC46A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13477 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130919-A1 | PRALATREXATE AND COP COMBINATION FOR THE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA | Acrotech Biopharma Inc. (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739317-A1 | PRALATREXATE AND COP COMBINATION FOR THE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA | Acrotech Biopharma Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-20260108621-A1 | Immune Cell Conjugates and Methods for Producing and Using the Same | Sandigene Inc. (US) | 2026-04-23 | — | — | US | claimed |
| EP-2387397-A2 | METHODS FOR IDENTIFYING PATIENTS WHO WILL RESPOND WELL TO CANCER TREATMENT | Topotarget A/S (DK) | 2011-11-23 | — | — | EP | claimed |
| WO-2011130689-A1 | POTENTIATION OF ANTI-CANCER ACTIVITY THROUGH COMBINATION THERAPY WITH BER PATHWAY INHIBITORS | TRACON PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | claimed |
| US-8038438-B2 | Totally adjustable bracket system | RUIZ DIAZ ROBERTO | 2011-10-18 | — | — | US | claimed |
| WO-2011119866-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2011-09-29 | — | — | WO | claimed |
| WO-2011113879-A1 | ENHANCED FOLIC ACID FLUORESCENT MATERIAL, MULTIFLUORESCENT POROUS COMPOSITIONS OF MATTER AND POTENTIAL APPLICATIONS THEREOF. | NANOLOGICA AB (SE) | 2011-09-22 | — | — | WO | claimed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20100190694-A1 | Methods for identifying patients who will respond well to cancer treatment | TOPOTARGET A/S (SE) | 2010-07-29 | — | — | US | claimed |
| WO-2010081662-A2 | METHODS FOR IDENTIFYING PATIENTS WHO WILL RESPOND WELL TO CANCER TREATMENT | TOPOTARGET A/S (DK) | 2010-07-22 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |